PXMD * Stock Overview
A clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
PaxMedica, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.69 |
| 52 Week High | US$711.79 |
| 52 Week Low | US$15.69 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| PXMD * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | -3.4% |
| 1Y | n/a | -20.4% | 1.3% |
Return vs Industry: Insufficient data to determine how PXMD * performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how PXMD * performed against the MX Market.
Price Volatility
| PXMD * volatility | |
|---|---|
| PXMD * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.4% |
Stable Share Price: PXMD * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PXMD *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 4 | Howard Weisman | www.paxmedica.com |
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. The company’s lead product candidate is PAX-101, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT.
PaxMedica, Inc. Fundamentals Summary
| PXMD * fundamental statistics | |
|---|---|
| Market cap | Mex$50.91m |
| Earnings (TTM) | -Mex$299.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs PXMD * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PXMD * income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.59m |
| Earnings | -US$17.59m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.88 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -294.5% |
How did PXMD * perform over the long term?
See historical performance and comparison